ClearFlow has been selected to exhibit PleuraFlow Active Clearance Technology (ACT), an FDA-cleared chest drainage system used during and after cardiothoracic surgery which features a proprietary active clearance mechanism that allows for the mechanical removal of intraluminal clots from the chest tube, proactively maintaining chest tube patency at the Vizient Innovative Technology Exchange. Vizient, the nation’s largest provider-driven healthcare performance improvement company, will hold the Exchange Sept. 17 in Las Vegas.

The annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their product or service to supply chain and clinical leaders from Vizient’s hospital clients and subject matter experts who serve on their supply councils. Each product or service will showcase how it improves clinical outcomes, enhances safety or drives incremental improvements to healthcare delivery or business models.

Maintenance of chest tube patency to prevent retained blood complications is a Class I, Level B-NR recommendation in the ERAS Cardiac Society Guidelines for Cardiac Surgery. PleuraFlow Active Clearance Technology (ACT) uniquely addresses a major failure mode of traditional drainage systems, chest tube occlusion, by proactively clearing intraluminal clots. This helps prevent Retained Blood Syndrome (RBS), a clinical composite associated with hemothorax, tamponade, re-explorations, and prolonged ICU and hospital stays. Multiple peer-reviewed studies have shown that PleuraFlow improves drainage, reduces complications, and enhances patient recovery.

“We are honored to be selected to present the PleuraFlow Active Clearance Technology System at the Vizient Innovative Technology Exchange,” said Hannah Beathard, CEO of ClearFlow, Inc. “Our mission is to help healthcare providers reduce preventable complications after cardiac surgery by proactively maintaining chest tube patency and thereby minimizing or preventing retained blood. We look forward to showing how PleuraFlow can improve patient outcomes, enhance recovery, and reduce costs for hospitals and health systems.”

“The Innovative Technology Exchange fosters a unique opportunity for healthcare providers to interact with products and services that have the potential to impact the healthcare industry and improve clinical care or the business model of organizations,” said Kelly Flaharty, senior director of contract services, Vizient. “We are pleased to invite ClearFlow to the Exchange.”

The annual Innovative Technology Exchange is part of Vizient’s Innovative Technology Program that includes product review of supplier-submitted technologies by provider-led councils. Since 2003, Vizient has reviewed over 1,700 product submissions as part of its Innovative Technology Program.

About ClearFlow, Inc.

ClearFlow, Inc. is an Irvine, CA based medical device company that has developed a patented active blood and fluid evacuation system to speed recovery, reduce complications and lower healthcare costs related to medical tube obstruction. The company has been awarded several prestigious awards, including the Global Frost & Sullivan Award for New Product Innovation, the European Association of Cardiothoracic Surgeons Techno-College Innovation Award for worldwide innovation that has the potential to change the standard of care in heart and lung surgery, and the Innovations in Cardiovascular Interventions Award, among others.

PleuraFlow and Active Clearance Technology are registered trademarks of ClearFlow, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250902841805/en/